메뉴 건너뛰기




Volumn 120, Issue 13, 2014, Pages 2016-2024

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma

(16)  Hamid, Omid a   Ilaria, Robert b   Garbe, Claus c   Wolter, Pascal d   Maio, Michele e   Hutson, Thomas E f   Arance, Ana g   Lorigan, Paul h   Lee, Jeeyun i   Hauschild, Axel j   Mohr, Peter k   Hahka Kemppinen, Marjo b   Kaiser, Christopher b   Turner, P Kellie b   Conti, Ilaria b   Grob, Jean Jacques l  


Author keywords

clinical trial; LY573636; melanoma; paclitaxel; phase 3 chemotherapy; tasisulam

Indexed keywords

PACLITAXEL; TASISULAM;

EID: 84902535288     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28635     Document Type: Article
Times cited : (19)

References (26)
  • 3
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363: 809-819.
    • (2010) N Engl J Med. , vol.363 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 4
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • BRIM-3 Study Group
    • Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
    • (2011) N Engl J Med. , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 5
    • 84857615145 scopus 로고    scopus 로고
    • Immunotherapy for metastatic melanoma
    • Zito CR, Kluger HM,. Immunotherapy for metastatic melanoma. J Cell Biochem. 2012; 113: 725-734.
    • (2012) J Cell Biochem. , vol.113 , pp. 725-734
    • Zito, C.R.1    Kluger, H.M.2
  • 6
    • 81055149894 scopus 로고    scopus 로고
    • Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization
    • Meier T, Uhlik M, Chintharlapalli S, et al. Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Mol Cancer Ther. 2011; 10: 2168-2178.
    • (2011) Mol Cancer Ther. , vol.10 , pp. 2168-2178
    • Meier, T.1    Uhlik, M.2    Chintharlapalli, S.3
  • 7
    • 0024312538 scopus 로고
    • Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
    • Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989; 81: 1088-1092.
    • (1989) J Natl Cancer Inst. , vol.81 , pp. 1088-1092
    • Paull, K.D.1    Shoemaker, R.H.2    Hodes, L.3
  • 8
    • 80053906313 scopus 로고    scopus 로고
    • A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma
    • Kirkwood JM, Gonzalez R, Reintgen D, et al. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011; 117: 4732-4739.
    • (2011) Cancer. , vol.117 , pp. 4732-4739
    • Kirkwood, J.M.1    Gonzalez, R.2    Reintgen, D.3
  • 9
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
    • (2000) J Natl Cancer Inst. , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 10
    • 0021325538 scopus 로고
    • Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)
    • Hill GJ 2nd, Krementz ET, Hill HZ,. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984; 53: 1299-1305.
    • (1984) Cancer. , vol.53 , pp. 1299-1305
    • Hill II, G.J.1    Krementz, E.T.2    Hill, H.Z.3
  • 11
    • 0033024863 scopus 로고    scopus 로고
    • High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    • Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17: 2105-2116.
    • (1999) J Clin Oncol. , vol.17 , pp. 2105-2116
    • Atkins, M.B.1    Lotze, M.T.2    Dutcher, J.P.3
  • 12
    • 60849138721 scopus 로고    scopus 로고
    • 2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM) [abstract]
    • Abstract 20023
    • Lawson DH, Gonzalez R, Weber RW, et al. 2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM) [abstract]. J Clin Oncol. 2008; 26. Abstract 20023.
    • (2008) J Clin Oncol. , vol.26
    • Lawson, D.H.1    Gonzalez, R.2    Weber, R.W.3
  • 13
    • 75749108097 scopus 로고    scopus 로고
    • Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM) [abstract]
    • Abstract LBA9012.
    • Hauschild A, Eggermont M, Jacobson E, O'Day SJ,. Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM) [abstract]. J Clin Oncol. 2009; 27 (18 suppl). Abstract LBA9012.
    • (2009) J Clin Oncol. , vol.27 , Issue.18 SUPPL.
    • Hauschild, A.1    Eggermont, M.2    Jacobson, E.3    O'Day, S.J.4
  • 14
    • 82455212082 scopus 로고    scopus 로고
    • A phase i study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
    • Simon GR, Ilaria RL Jr, Sovak MA, et al. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2011; 68: 1233-1241.
    • (2011) Cancer Chemother Pharmacol. , vol.68 , pp. 1233-1241
    • Simon, G.R.1    Ilaria, Jr.R.L.2    Sovak, M.A.3
  • 15
    • 84879462090 scopus 로고    scopus 로고
    • Tailored dosing of tasisulam sodium (LY573636 sodium) to reduce hematological toxicity and improve therapeutic index
    • Abstract 286.
    • de Alwis D, Cleverly A, Chow K, Troconiz I, Ilaria R,. Tailored dosing of tasisulam sodium (LY573636 sodium) to reduce hematological toxicity and improve therapeutic index. EJC Suppl. 2010; 8: 92-93. Abstract 286.
    • (2010) EJC Suppl. , vol.8 , pp. 92-93
    • De Alwis, D.1    Cleverly, A.2    Chow, K.3    Troconiz, I.4    Ilaria, R.5
  • 16
    • 3242881591 scopus 로고    scopus 로고
    • National Cancer Institute. Cancer Therapy Evaluation Program Accessed May 13
    • National Cancer Institute. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0 (CTCAE). ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed May 13, 2013.
    • (2013) Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
  • 17
    • 33845382806 scopus 로고
    • Nonparametric estimation of incomplete observations
    • Kaplan E, Meier P,. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
    • (1958) J Am Stat Assoc. , vol.53 , pp. 457-481
    • Kaplan, E.1    Meier, P.2
  • 18
    • 84872320891 scopus 로고    scopus 로고
    • A phase i study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors
    • Gordon MS, Ilaria R Jr, de Alwis DP, et al. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013; 71: 21-27.
    • (2013) Cancer Chemother Pharmacol. , vol.71 , pp. 21-27
    • Gordon, M.S.1    Ilaria, Jr.R.2    De Alwis, D.P.3
  • 21
    • 0026013307 scopus 로고
    • A phase II study of taxol in patients with malignant melanoma
    • Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs. 1991; 9: 59-64.
    • (1991) Invest New Drugs. , vol.9 , pp. 59-64
    • Einzig, A.I.1    Hochster, H.2    Wiernik, P.H.3
  • 23
    • 0142057351 scopus 로고    scopus 로고
    • Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG)
    • Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003; 13: 531-536.
    • (2003) Melanoma Res. , vol.13 , pp. 531-536
    • Zimpfer-Rechner, C.1    Hofmann, U.2    Figl, R.3
  • 24
    • 67649909568 scopus 로고    scopus 로고
    • Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
    • Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009; 27: 2823-2830.
    • (2009) J Clin Oncol. , vol.27 , pp. 2823-2830
    • Hauschild, A.1    Agarwala, S.S.2    Trefzer, U.3
  • 25
    • 0033015901 scopus 로고    scopus 로고
    • One-hour paclitaxel infusions: Review of safety and efficacy
    • Greco FA, Thomas M, Hainsworth JD,. One-hour paclitaxel infusions: review of safety and efficacy. Cancer J Sci Am. 1999; 5: 179-191.
    • (1999) Cancer J Sci Am. , vol.5 , pp. 179-191
    • Greco, F.A.1    Thomas, M.2    Hainsworth, J.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.